Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Azetidines
/ pharmacology
Histiocytic Disorders, Malignant
/ drug therapy
Histiocytosis
/ drug therapy
Humans
MAP Kinase Kinase 1
/ antagonists & inhibitors
MAP Kinase Kinase 2
/ antagonists & inhibitors
MAP Kinase Signaling System
/ drug effects
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Mutation
Piperidines
/ pharmacology
Progression-Free Survival
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins c-raf
/ genetics
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
09
11
2018
accepted:
11
02
2019
pubmed:
15
3
2019
medline:
29
10
2019
entrez:
15
3
2019
Statut:
ppublish
Résumé
Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway
Identifiants
pubmed: 30867592
doi: 10.1038/s41586-019-1012-y
pii: 10.1038/s41586-019-1012-y
pmc: PMC6438729
mid: NIHMS1521555
doi:
Substances chimiques
Azetidines
0
Piperidines
0
MAP2K2 protein, human
EC 2.7.1.-
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins c-raf
EC 2.7.11.1
Raf1 protein, human
EC 2.7.11.1
MAP Kinase Kinase 1
EC 2.7.12.2
MAP Kinase Kinase 2
EC 2.7.12.2
MAP2K1 protein, human
EC 2.7.12.2
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
cobimetinib
ER29L26N1X
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-524Subventions
Organisme : NCI NIH HHS
ID : K08 CA218901
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201247
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210085
Pays : United States
Références
Nature. 2006 Jan 19;439(7074):358-62
pubmed: 16273091
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Blood. 2014 Sep 4;124(10):1655-8
pubmed: 24982505
Blood. 2014 Nov 6;124(19):3016-9
pubmed: 25150293
Blood. 2014 Nov 6;124(19):3007-15
pubmed: 25202140
Blood. 2015 Jul 2;126(1):26-35
pubmed: 25827831
Blood. 2018 Jun 28;131(26):2877-2890
pubmed: 29720485
Cancer Discov. 2016 Feb;6(2):154-65
pubmed: 26566875
Blood. 2017 Oct 5;130(14):1644-1648
pubmed: 28801450
JAMA Oncol. 2018 Mar 1;4(3):384-388
pubmed: 29188284
Blood. 2012 Sep 27;120(13):2700-3
pubmed: 22879539
Lancet Oncol. 2012 Aug;13(8):782-9
pubmed: 22805292
Lancet Oncol. 2017 Feb;18(2):e113-e125
pubmed: 28214412
Blood. 2014 May 15;123(20):3152-5
pubmed: 24652991
Blood. 2016 Nov 24;128(21):2533-2537
pubmed: 27729324
Cancer Res. 2008 Nov 15;68(22):9375-83
pubmed: 19010912
Blood. 2014 Jul 24;124(4):483-92
pubmed: 24850756
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Invest New Drugs. 2016 Oct;34(5):604-13
pubmed: 27424159
Cancer Discov. 2018 May;8(5):648-661
pubmed: 29483135
N Engl J Med. 2017 Dec 14;377(24):2398-2399
pubmed: 29236635
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6
pubmed: 19915144
Blood. 2011 Mar 10;117(10):2778-82
pubmed: 21239701
J Clin Oncol. 2013 Jan 20;31(3):398
pubmed: 23248255
N Engl J Med. 2018 Aug 30;379(9):856-868
pubmed: 30157397
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
N Engl J Med. 2018 May 17;378(20):1945-1947
pubmed: 29768143
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821